Telix Pharmaceuticals Reports Strong Full-Year Revenue, But Shares Remain Under Pressure

Telix Pharmaceuticals Limited (NASDAQ:TLX), a therapeutic and diagnostic radiopharmaceuticals company, on Tuesday reported its full-year revenue. • Telix Pharmaceuticals stock is testing lower boundaries. Why is TLX stock at lows? Telix Hits FY 2025 Revenue Target Australia-based Telix Pharmaceuticals reported fiscal 2025 revenue of approximately $804 million, aligning with its upgraded guidance of $800-$820 million. The company also noted a significant 46% year-over-year increase in the fourth quarter revenue, totaling around $208 million. In addition, the Precision Medicine business generated approximately $161 million in revenue, reflecting a 4% quarter-over-quarter growth driven by the successful U.S. launch of Gozellix following its reimbursement approval by the Centers for Medicare and Medicaid Services (CMS) effective Oct. 1, 2025. The company is also advancing its clinical studies, with international patients treated in the ProstACT Global Phase 3 study and the SOLACE Phase 1 study in the U.S. Last week, Telix Pharmaceuticals dosed the first patient in the U.S. in the BiPASS Phase 3 trial to evaluate the use of Telix’s commercial PSMA-PET imaging agents, Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection) and Gozellix (kit for the preparation of gallium Ga 68 gozetotide injection) in the initial prostate cancer diagnosis setting. The company also announced a strategic collaboration with Varian, a Siemens Healthineers company, to explore the combination of Telix’s radiopharmaceuticals with external beam radiation therapy. Telix Stock Faces Bearish Trend; Down 56.91% Over Past 12 Months The stock is currently trading 5.5% below its 20-day simple moving average (SMA) and 22.6% below its 100-day SMA, indicating a bearish trend in the short to medium term. Over the past 12 months, shares have decreased by 56.91% and are positioned closer to their 52-week lows than highs, reflecting ongoing challenges for the stock. The RSI is at 41.91, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold. Meanwhile, MACD is above its signal line, indicating a potential bullish momentum despite the overall bearish trend. The combination of neutral RSI and bullish MACD suggests mixed momentum for the stock. Key Resistance: $8 Key Support: $7 Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $21.20. Recent analyst moves include: HC Wainwright & Co.: Buy (Target $20 on Jan. 21) UBS: Buy (Lowered Target to $20 on Sept. 23, 2025) William Blair said Tuesday that the bull case for Telix rests on its shift from a primarily diagnostic-focused business to a pure-play radiopharmaceutical company built around theranostics, which combine diagnostics and therapeutics. Analyst Andy Hsieh maintains the Outperform rating and said that Illuccix/Gozellix can generate durable and expanding cash flows to support this transition. Valuation Insight: While the stock trades at a premium P/E multiple, the strong consensus and 15% expected earnings growth suggest analysts view this growth as justification for the 194% upside to analyst targets. Benzinga Edge: Telix Scores Low on Momentum Below is the Benzinga Edge scorecard for Telix Pharmaceuticals, highlighting its strengths and weaknesses compared to the broader market: Momentum: Bearish (Score: 1.84/100) — Stock is underperforming the broader market. Value: Risk (Score: 6.41/100) — Trading at a steep premium relative to peers. The Verdict: Telix Pharmaceuticals’ Benzinga Edge signal reveals a challenging outlook. The extremely low Momentum score indicates the stock is struggling significantly, while the Value score suggests it is trading at a premium, which may deter potential investors. TLX Price Action: Telix Pharmaceuticals shares were down 6.86% at $7.20 at the time of publication on Wednesday, according to Benzinga Pro data. Photo: jittawit21 via Shutterstock